Entecavir monotherapy in children with chronic hepatitis B in early life of children may improve the HBsAg seroconversion
Objective To explore the efficacy of Entecavir monotherapy in children with chronic hepatitis B(CHB)in different ages.Methods A total of 38 CHB children outpatients of the First Affiliated Hospital of Xi'an Jiaotong University from Jun.2013 to Mar.2023 were enrolled into this retrospective study who were received Entecavir mono-therapy at least 24 weeks.The changes of liver function,hepatitis B virus serum markers,HBV DNA and adverse reac-tions of the 38 children were observed.Results The median antiviral age of the 38 children was 6.3 years old(2.0-14.6 years old).The median follow-up time was 3.6 years(0.6-9.8 years).Thirty-five children(92.1％)had ALT normalization.HBV DNA was undetected in 29 children(76.3％),HBeAg was undetected in 16 children(45.7％),and HBsAg was undetected in 7 children(18.4％).The rate of HBeAg loss(88.9％vs 30.8％,P=0.0049)and HBsAg loss(60.0％vs 3.6％,P=0.0005)were significantly higher in children under 3 years old,compared with those in children older than 3 years old.Conclusion The initiation of Entecavir monotherapy before 3 years old in children with chronic hepatitis B may improve the HBsAg seroconversion.
Hepatitis B virusChildrenEntecavirChronic hepatitis B
万方数据
维普
